Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
作者信息
Klil-Drori Adi J, Yin Hui, Azoulay Laurent, Harnois Michaël, Gratton Michel-Olivier, Busque Lambert, Assouline Sarit E
机构信息
Center for Clinical Epidemiology, Jewish General Hospital, Montreal, QC.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC.
出版信息
Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10.
Abstract
摘要
相似文献
1
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.慢性髓性白血病使用通用型伊马替尼的持续性：一项匹配队列研究。
Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10.
2
What Happens When Imatinib Goes Generic?伊马替尼成为非专利药后会发生什么？
J Natl Compr Canc Netw. 2016 Feb;14(2):128-31. doi: 10.6004/jnccn.2016.0016.
3
The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.通用型伊马替尼作为一线和二线治疗的疗效：慢性髓性白血病患者的3年随访
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):238-240. doi: 10.1016/j.clml.2017.02.001. Epub 2017 Feb 16.
4
Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.伊马替尼的仿制药治疗儿童费城染色体阳性白血病。
Pediatr Blood Cancer. 2018 Dec;65(12):e27431. doi: 10.1002/pbc.27431. Epub 2018 Aug 30.
5
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.在引入仿制药治疗慢性髓性白血病患者的癌症时，患者需要质量和一致性。
Leukemia. 2016 Dec;30(12):2396-2397. doi: 10.1038/leu.2016.220. Epub 2016 Aug 3.
6
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.约旦人使用伊马替尼通用疗法：常规临床实践中疗效与安全性的观察性评估
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e55-e61. doi: 10.1016/j.clml.2017.08.001. Epub 2017 Aug 5.
7
Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.曲妥珠单抗仿制药的可及性和定价与慢性髓性白血病患者酪氨酸激酶抑制剂使用趋势的关系。
JAMA Oncol. 2020 Dec 1;6(12):1969-1971. doi: 10.1001/jamaoncol.2020.4660.
8
Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.通用型伊马替尼治疗慢性髓性白血病：拉脱维亚的两年经验。
Exp Oncol. 2017 Jul;39(2):151-154.
9
The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib.慢性髓性白血病患者中TNF和IL6基因表达的动态变化揭示了对伊马替尼的早期反应者。
Leuk Res. 2019 Nov;86:106221. doi: 10.1016/j.leukres.2019.106221. Epub 2019 Sep 4.
10
[A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study].中国仿制伊马替尼与原研伊马替尼治疗新诊断慢性期慢性髓性白血病患者的疗效和安全性比较：一项单中心前瞻性队列研究
Zhonghua Nei Ke Za Zhi. 2016 Dec 1;55(12):922-926. doi: 10.3760/cma.j.issn.0578-1426.2016.12.003.
引用本文的文献
1
Comment on: "Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study" by Busque et al.对Busque等人所著的《慢性粒细胞白血病治疗期间频繁更换酪氨酸激酶抑制剂，主要由不耐受驱动，且不影响生存率：一项魁北克前瞻性登记研究》的评论
Blood Cancer J. 2025 Apr 19;15(1):70. doi: 10.1038/s41408-025-01288-8.
2
Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data.比利时慢性髓性白血病患者的伊马替尼依从性和持续性：来自真实世界数据的证据
Patient Prefer Adherence. 2024 Sep 25;18:1991-2006. doi: 10.2147/PPA.S472478. eCollection 2024.
3
Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.停用伊马替尼治疗达到缓解的可行性：在慢性髓性白血病慢性期研究中使用非专利伊马替尼的试验结果。
Indian J Med Res. 2023 Jan;157(1):87-91. doi: 10.4103/ijmr.ijmr_1090_21.
4
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.目前关于通用伊马替尼在 CML 中的疗效和安全性的证据，以及仿制药对医疗保健成本的影响。
Blood Adv. 2021 Sep 14;5(17):3344-3353. doi: 10.1182/bloodadvances.2021004194.
5
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.通用型伊马替尼用于慢性粒细胞白血病（CML）患者一线治疗：GIMS（格列卫至伊马替尼转换）研究
Blood Res. 2020 Sep 30;55(3):139-145. doi: 10.5045/br.2020.2020130.
6
The tolerability issue of generic imatinib in patients with chronic myeloid leukemia .慢性髓性白血病患者中通用型伊马替尼的耐受性问题
Haematologica. 2019 Jul;104(7):e330. doi: 10.3324/haematol.2019.222000.
本文引用的文献
1
Outcome of Frontline Treatment with "Generic" Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study.阿尔及利亚人群中成年慢性髓性白血病患者使用“通用型”伊马替尼一线治疗的结果：一项多中心研究
Mediterr J Hematol Infect Dis. 2017 Oct 25;9(1):e2017062. doi: 10.4084/MJHID.2017.062. eCollection 2017.
2
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.伊马替尼仿制药疗效与安全性的多中心前瞻性研究：波兰成人白血病组伊马替尼仿制药注册报告
Am J Hematol. 2017 Jul;92(7):E125-E128. doi: 10.1002/ajh.24748. Epub 2017 May 26.
3
The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.通用型伊马替尼作为一线和二线治疗的疗效：慢性髓性白血病患者的3年随访
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):238-240. doi: 10.1016/j.clml.2017.02.001. Epub 2017 Feb 16.
4
Generic oncology drugs: are they all safe?通用肿瘤药物：它们都安全吗？
Lancet Oncol. 2016 Nov;17(11):e493-e501. doi: 10.1016/S1470-2045(16)30384-9.
5
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.在引入仿制药治疗慢性髓性白血病患者的癌症时，患者需要质量和一致性。
Leukemia. 2016 Dec;30(12):2396-2397. doi: 10.1038/leu.2016.220. Epub 2016 Aug 3.
6
Bias from historical control groups used in orthodontic research: a meta-epidemiological study.正畸研究中使用历史对照组的偏倚：一项元流行病学研究。
Eur J Orthod. 2017 Feb;39(1):98-105. doi: 10.1093/ejo/cjw035. Epub 2016 Apr 29.
7
Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors: A Qualitative Study.影响口服酪氨酸激酶抑制剂的癌症患者依从性的因素：一项定性研究
Cancer Nurs. 2016 Mar-Apr;39(2):153-62. doi: 10.1097/NCC.0000000000000250.
8
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.使用甲磺酸伊马替尼通用制剂对慢性期慢性髓性白血病患者进行一线治疗。
Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10.
9
Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.用于治疗慢性期慢性髓性白血病患者的伊马替尼非品牌版本的有害影响：关于一个影响患者安全的不断升级问题的病例系列。
Leuk Lymphoma. 2014 Dec;55(12):2813-6. doi: 10.3109/10428194.2014.893302. Epub 2014 Jun 17.
10
Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.慢性期慢性髓性白血病的前瞻性单中心研究：从原研伊马替尼转换为仿制药再换回原研药。
Leuk Lymphoma. 2014 Dec;55(12):2830-4. doi: 10.3109/10428194.2014.904508. Epub 2014 Apr 22.
Zotero 插件